23 citations
,
December 2004 in “Seminars in oncology” This study found that DVd therapy is at least as effective as VAD/VAd for treating multiple myeloma and causes fewer side effects and reduced hospital visits.
This study found that in an ex vivo model simulating alopecia areata, the DHODH inhibitor farudodstat reduced T-cell proliferation and MHC protein expression in hair follicles, suggesting it may protect against immune privilege collapse without cytotoxic effects.
May 2026 in “BMC Medicine” This study found that ACOD1 deficiency in dermal papilla cells promotes mitochondrial dysfunction and contributes to cellular senescence in androgenetic alopecia, suggesting ACOD1 as a potential therapeutic target and 4-octyl itaconate as a promising treatment option for AGA.
June 2024 in “Zagazig University Medical Journal” This study found that intralesional vitamin D injections in patients with alopecia areata resulted in mild effectiveness, with minimal hair regrowth observed in 75% of patients, and no significant change in SALT scores post-treatment compared to baseline.
January 2026 in “JPRAS Open” In this pilot study, PDLLA scalp microinjections showed improvement in physician-rated Global Aesthetic Improvement Scale scores over 12-24 weeks for 90% of patients with non-scarring alopecia, with no serious adverse events reported, although findings remain preliminary due to methodological limitations.
23 citations
,
August 2022 in “JAMA Dermatology” In this study, patients with alopecia areata indicated a preference for shared decision-making (SDM) with their dermatologists, and those who engaged in SDM reported less decisional regret about their treatment choices.
November 2021 in “Journal of Regenerative Biology and Medicine” This article discusses alopecia areata, an inflammatory hair loss condition with largely unexplored causes, but provides no new research findings.
July 2025 in “Jurnal Farmasi Sains dan Praktis” This study found that breast cancer patients treated with the docetaxel-doxorubicin regimen experienced various adverse drug reactions, with nausea being the most common and mainly mild in severity.
August 2025 in “International Journal of Research in Ayurveda and Pharmacy” In this study, significant relief from symptoms of Darunaka, such as itching and dryness, was observed in a 14-year-old patient following treatment with an Ayurvedic formulation made from mango seed and Terminalia chebula powders.
1 citations
,
January 2018 in “Journal of Steroids & Hormonal Science” This study observed no significant difference in vitamin D levels between children with alopecia areata and controls, but higher complete improvement in alopecia was noted among patients with vitamin D deficiency undergoing oral vitamin D treatment.
May 2026 in “Jurnal Sehat Indonesia (JUSINDO)” This systematic review found an inverse relationship between vitamin D levels and the severity, extent, and pattern of alopecia areata, suggesting vitamin D deficiency may contribute to or worsen this autoimmune hair loss condition.
208 citations
,
November 2000 in “Development” This study found that while Eda and Edar proteins interact in vitro, their roles in dental development differ, with downless mutant mice showing distinct tooth defects compared to tabby mutants.
August 2020 in “European Journal of Dermatology” This study identified three EDAR gene variants potentially linked to hypohidrotic ectodermal dysplasia in three Pakistani families, which could aid in genetic counseling for similar cases.
1 citations
,
March 2023 in “Frontiers in Cardiovascular Medicine” A specific gene variant is linked to heart disease, increased heart muscle, curly hair, and thick skin on palms and soles.
May 2024 in “Nano letters” This study developed a quercetin-encapsulated and polydopamine-integrated nanosystem that reshapes the perifollicular microenvironment, showing potential for rescuing hair follicle viability and regenerating hair follicles in androgenic alopecia by scavenging reactive oxygen species and promoting angiogenesis.
September 2023 in “Journal of the American Academy of Dermatology” This study found that in participants with notalgia paresthetica, 8 weeks of treatment with difelikefalin significantly improved itch intensity and increased the rate of strict complete response compared to placebo, starting as early as week 3.
September 2009 in “Annales D Endocrinologie” This article reviews the clinical signs, diagnostic approaches, and treatment options for hyperandrogenism in women, focusing on hirsutism and specifies that cyproterone acetate is effective for severe cases, but reports no new clinical results.
1 citations
,
November 2024 in “European Journal of Endocrinology” This study observed that higher childhood levels of DHEAS were associated with more advanced pubertal development and correlated with changes in DNA methylation near puberty-related genes in both boys and girls, potentially explaining the hormone's influence on puberty.
May 2026 in “Mendeley Data” This abstract provides supplementary materials for a study on the efficacy and safety of a topical siRNA-based formulation targeting DKK-1 for androgenetic alopecia, but reports no new findings.
November 2025 in “British Journal of Dermatology” This guideline by the British Association of Dermatologists reviews managing alopecia areata and provides 56 recommendations but reports no new clinical results.
August 2024 in “British Journal of Dermatology” The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.
1 citations
,
April 2019 in “Journal of Investigative Dermatology” This study examined the safety and efficacy of dupilumab in adolescents with moderate-to-severe atopic dermatitis, finding that it was well tolerated and significantly improved symptoms over 52 weeks, with its safety profile similar to that in adults.
22 citations
,
January 2015 in “The Cochrane library” This review found no evidence that DHEA improves quality of life or decreases menopausal symptoms in peri- and postmenopausal women, but it may slightly enhance sexual function compared to placebo.
19 citations
,
January 2016 in “Annals of Dermatology” This study found that dutasteride 0.5 mg was generally well-tolerated and led to overall improvement in male patients aged 18 to 41 with androgenic alopecia in a Korean clinical practice setting.
82 citations
,
January 2000 in “Hormone Research in Paediatrics” This study describes the enzymatic processes through which DHEA is converted to active sex steroids in human skin, highlighting an androgenic effect on sebaceous glands and estrogenic effects in the vagina.
August 2023 in “Journal of Investigative Dermatology” In this meta-analysis, researchers found that oral dutasteride may stabilize or improve frontal fibrosing alopecia in patients, but results varied widely, and further controlled studies are needed to confirm its effectiveness as a treatment option.
January 2011 in “Guangdong Medical Journal” This study observed that Vitamin D receptor expression at protein and mRNA levels was significantly lower in the hair follicles of alopecia areata patients compared to healthy individuals.
2 citations
,
January 2012 in “Journal of Clinical & Experimental Dermatology Research” This study found that adding fexofenadine to DPCP treatment in non-atopic Alopecia areata patients did not significantly improve hair regrowth, but it did significantly reduce treatment-related discomfort.
This study reported that dandelion herb-derived carbon dots significantly enhanced wound healing in mice with Staphylococcus aureus infections, outperforming a commercial wound healing spray through their antibacterial and dual ROS-modulating capabilities.
2 citations
,
March 2015 in “Hepatitis Monthly” This case report identified dystrophic anagen effluvium as a previously unreported dermatological side effect of PEG-INF-α-2a/RBV combination therapy in a patient with chronic hepatitis C infection.